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APOBEC cytidine deaminases have been implicated as
major contributors to the mutation burden in many
cancers on the basis of their mutational signature. A
new experimental study sheds light on the inciting
factors, linking APOBEC3B expression to oncogene-
and drug-induced replication stress.observed in cancer. Following these discoveries, effortsFootprints in the genome: from patterns to
processes
The Cancer Genome Atlas (TCGA) Project has been an
undisputed success in advancing our knowledge of the
many and varied subtypes of cancer. The identification
of recurrent somatic alterations, patterns of gene expression
and relationships between these have provided a crucial re-
source to inform our understanding of cancer biology and
the development of biomarker-driven therapeutic strategies.
Moreover, analysis of the types of mutations in these estab-
lished cancers has revealed mutational signatures that re-
flect the processes that contributed to their genesis [1]. As
expected, the mutational footprints of tobacco smoking
and ultraviolet damage feature prominently in the cancers
where epidemiologic links are established and well under-
stood. More interesting, however, are those that were un-
anticipated, such as the pattern of base changes consistent
with the mutagenic activity of the endogenous APOBEC3
cytidine deaminases. In a recently published study, Kanu
and colleagues from the Swanton laboratory investigate the
molecular basis of this phenomenon in breast cancer cell
lines [2].
The APOBEC enzymes primarily function in innate
antiviral immunity and deaminate cytosine to uracil in
single-stranded DNA to generate C > T and C >G muta-
tions in a preferential motif. Many solid tumors bear these
genomic hallmarks and are believed to reflect the damage* Correspondence: dave.cescon@uhn.ca; bhaibeka@uhnresearch.ca
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cancer datasets [3, 4], the mutagenic potential of the APO-
BEC family of enzymes had been recognized in preclinical
systems, but the inferred mutational burden across a high
proportion of tumor types represented a surprising dis-
covery. Of the candidate APOBECs capable of such
mutagenesis, APOBEC3B was fingered as the most
likely culprit—in large part because of its overexpression
quickly turned to the study of the upstream mechanisms
of APOBEC dysregulation and the downstream conse-
quences of this activity, in order to characterize this novel
biology and pursue potential opportunities for cancer pre-
vention or treatment.
The complexity of this undertaking is significant. The
seven human APOBEC3 family members share signifi-
cant homology, which limits the availability of reagents
with high specificity. In addition, mice only have a single
APOBEC3, meaning that mouse models have limited ex-
perimental application. Furthermore, the biology is com-
plicated by the existence of a common human germline
deletion polymorphism in APOBEC3B, which eliminates
the entire coding region of this gene but is paradoxically
associated with an increased risk of breast cancer [5]
and an increased burden of APOBEC-pattern mutations
[6, 7]. It has been suggested recently that APOBE-
C3A—rather than 3B—might be responsible for the bulk
of APOBEC mutations in highly APOBEC-mutated tu-
mors [7], but, in light of the low levels of APOBEC3A
expression in epithelial cells, the mechanism for this re-
mains unclear.Connecting replication stress and APOBEC3B
through ATR
Kanu and colleagues focused on the association between
replication stress and APOBEC3B activity in breast
cancer cell lines, starting from the observation that the
HER2-enriched subtype of breast cancers exhibits the
greatest burden of APOBEC mutations [8] and the premise
that oncogene-induced replication stress exposes single-le is distributed under the terms of the Creative Commons Attribution 4.0
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mutagenesis [2]. They observe a trend of increased
APOBEC3B, but not APOBEC3A or APOBEC3G, ex-
pression in HER2-enriched cell lines and demonstrate
a correlation between the presence of markers of replica-
tion stress and both APOBEC3B expression and biochem-
ical APOBEC3 deamination activity under basal conditions.
Nucleoside supplementation to relieve replication stress
resulted in a reduction in APOBEC3B expression and
APOBEC3 activity, supporting this association. Treat-
ment of the MCF10A non-tumorigenic breast epithelial
cell line with nine DNA-damaging or anti-metabolite
drugs followed by measurement of the ssDNA damage
marker pS4/8 RPA identified a relationship between those
that induced the highest levels of both APOBEC3B and
RPA phosphorylation, although this was not entirely
reproduced in the estrogen-receptor-positive MCF7
breast cancer cell line.
In their study, the authors also showed that the APO-
BEC3B upregulation following induction of replication
stress is dependent on signaling through the ATR–CHK1
(checkpoint kinase 1) pathway, providing a mechanism for
the observed phenomena. While not a primary focus of
the paper, the authors examined the association between
APOBEC3B expression and drug sensitivities. Interest-
ingly, they noted a trend between APOBEC3B expression
levels and in vitro sensitivity to the novel oral CHK1
inhibitor CCT244747 and speculated that markers of
replication stress, including APOBEC3B, could be useful to
predict response to this agent. While CCT244747 is not in-
cluded in the recent GDSC1000 pharmacogenomic dataset,
we did not observe a relationship between APOBEC3B ex-
pression and either AZD7762 or Calbiochem 681640,
which inhibit CHK1 (Additional file 1: Supplementary
methods; Additional file 2: Table S1), although the target
selectivities of these three drugs do vary. By contrast, the
authors observed no correlation between APOBEC3B ex-
pression and sensitivity to the DNA-damaging and anti-
metabolite drugs in their small panel of breast cancer cell
lines—results we confirmed in GDSC1000 (Additional file
2: Table S1a, b). However, when considering all cancer
types and cell lines, APOBEC3A and APOBEC3B ex-
pression was significantly associated with sensitivity to
16 and 38 drugs, respectively (false discovery rate <5 %,
correlation adjusted for tissue type; Additional file 2:
Table S1c, d), raising the possibility that expression of
these genes could mediate or mark sensitivity to anti-
cancer agents.
Together, this report presents an important contribu-
tion to the understanding of APOBEC3 dysregulation in
cancer and is consistent with our previous observation
that APOBEC3B is highly correlated with proliferation-
related gene expression in large breast cancer datasets
and across nearly all solid tumor types in TCGA [9]. Theconnection made here between replication stress and
APOBEC upregulation highlights a particularly vulnerable
context, where high levels of APOBEC3B enzyme and
ssDNA substrate co-exist. It will be of great interest to
see how generalizable the drug-induced upregulation
of APOBEC3B is across cancer cell lines and to assess
the impact of a broader group of drugs on APOBEC
expression.Minding the As and Bs
There remain many unanswered questions that must
be addressed in order to decipher the APOBEC puzzle
and translate these discoveries towards the clinic. Im-
portantly, evidence that upregulation of APOBEC3B
contributes to therapeutic resistance or that its modu-
lation improves disease control or anti-tumour activity
of other agents is lacking. The widely reported associ-
ations between increased APOBEC3B expression and
outcomes in patients are likely confounded by the fact
that its expression reflects a proliferative state. Indeed,
while expression levels point towards APOBEC3B as
the guilty party, the increase in cancer risk among germ-
line APOBEC3B deletion carriers [5] and the increased
burden of APOBEC-pattern mutations [6] attributed to
APOBEC3A [7] seen in these patients highlights key unre-
solved issues.
As Kanu and colleagues show, APOBEC3A is barely
detectable in breast cancer cell lines and was not increased
by the stimuli that induced APOBEC3B. Whether or
how APOBEC3A, with its potent enzymatic activity,
could be upregulated transiently under some condition
to strike in a “hit-and-run” fashion is unknown. How-
ever, our analysis of breast cancer gene expression data
shows clearly that the correlates of APOBEC3B expres-
sion in tumors (proliferation) are distinct from all of
the other members of the APOBEC3 family, which are
very strongly associated with a STAT1/interferon sig-
nature [9]. This observation, together with the experi-
mental data reported here, suggests that the inciting
triggers for APOBEC3A and APOBEC3B expression
are likely to differ.
In conclusion, Kanu and colleagues provide import-
ant insights into our understanding of the APOBEC
phenomenon. Their careful experimentation comple-
ments the growing body of genomics-based analyses
that seek to fully decrypt how and why these immune
defenders turn against our genomes. Well-conducted
experimental studies and continued interrogation of
the genomes of nascent and late-stage cancers, both
before and following treatment, will undoubtedly reveal
much about this enemy within and should clarify the po-
tential of translating this knowledge for the prevention or
treatment of cancers where APOBEC operates.
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